AbbVie stock reports 10.2 percent revenue growth
Published on 09/30/2026 at 16:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock was trading at EUR 232.35 at Lang & Schwarz on September 30, 2026, down 0.11 percent versus the prior close of EUR 232.60. The latest quarterly figures combined double-digit revenue growth with a modest earnings beat, while FDA approval for JUVMO adds a new commercial asset.
Quarterly revenue beats consensus
According to MarketBeat on September 29, 2026, AbbVie reported USD 16.99 billion in revenue for the quarter ended June 30, 2026, up 10.20 percent year over year. Adjusted EPS reached USD 3.65, exceeding the USD 3.61 consensus by USD 0.04.
The comparison matters because revenue also topped the USD 16.80 billion analyst estimate. AbbVie guided to adjusted Q3 2026 EPS of USD 3.84-3.88, extending the earnings story beyond the completed quarter.
Analysts set targets above USD 272.66
MarketBeat reported on September 29, 2026, that 31 brokerages assigned AbbVie a Moderate Buy consensus, with 23 buy ratings, two strong-buy ratings and six hold ratings. The average one-year price target was USD 272.66.
The pipeline supplies the other side of the investment case. MarketBeat highlighted FDA approval of JUVMO, a once-daily Parkinson's disease treatment, while also noting that analysts expect a gradual revenue ramp as physicians and patients adopt the therapy.
Lang & Schwarz quote is EUR 232.35
At 4:02 p.m. CEST on September 30, 2026, AbbVie was trading at EUR 232.35 at Lang & Schwarz. The price was minus 0.11 percent versus the Lang & Schwarz prior close of EUR 232.60 dated September 29, 2026.
The primary-market context was USD 263.30 on September 30, 2026, with a 52-week range of USD 190.75 to USD 269.39 and market capitalization of USD 465.2 billion. AbbVie is a biopharmaceutical company focused on medicines across immunology, oncology, neuroscience and other specialty areas.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of September 30, 2026, 4:02 p.m. CEST): EUR 232.35
- Change versus prior close: minus 0.11 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 232.60
- Market capitalization: USD 465.2 billion (as of September 30, 2026)
- 52-week range: USD 190.75-269.39 (as of September 30, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
